Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-Daily HAART (3TC + ddI + EFV) in HIV-1 Infected Children
NCT00122538Phase 2Completed
- Sponsor
- ANRS
- Start
- Feb 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine, didanosine and efavirenz in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ANRS. Primary endpoints: Percentage of patients with HIV RNA less than 400 copies per ml and less than 50 copies per ml at 24 months, Cmin and Cmax for the three drugs at 15 days and 1 more. Started Feb 2006; status: completed.
02
Drugs
lamivudinedidanosineefavirenz
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00122538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122538.